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LIVER TRANSPLANTATION 
Transplantation of the liver, as originally conceived, was first re-
ported in 1955 as an auxiliary liver transplant in which the native liver 
was preserved in its normal position and the new liver placed at a 
heterotopic site, usually the right paravertebral gutter, with portal inflow 
supplied with systemic blood via the inferior vena cava or iliac vein. 
Orthotopic liver transplantation is the accepted procedure today. The 
native liver is removed and replaced by a liver allograft in its normal 
location. The most common type of transplantation encompasses five 
anastomoses: the suprahepatic vena cava, the infrahepatic vena cava, 
the portal vein, the hepatic artery, and the biliary reconstruction. 
Indications for Liver Transplantation 
The indications for liver transplantation have evolved concomitantly 
with all aspects of this field and presently include cirrhosis (posthepatic, 
alcoholic, autoimmune, cryptogenic), cholestatic liver disease (primary 
biliary cirrhosis, sclerosing cholangitis, biliary atresia), neoplasm, fulmi-
nant hepatic failure, and inborn errors of metabolism. There has been 
progress in the continuing struggle to identify, treat and prevent a 
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variety of complications to which the liver transplant recipient is subject. 
These complications may include postoperative bleeding, technical com-
plications with any of multiple vascular and biliary anastomoses, infec-
tions, and graft dysfunction. 
Advances Made Possible by FK506 (Tacrolimus) 
The struggle to develop clinical liver transplantation to its present 
status has spanned 3 decades. Advances in organ preservation, surgical 
techniques, and peri- and postoperative care have been essential compo-
nents of this success. However, only with improvements in immunosup-
pressive regimens and treatment of allograft rejection was this parallel 
evolution translated into acceptable patient survival. With the introduc-
tion of cyclosporine in 1980 liver transplantation was expanded to permit 
universal applicability. It is currently performed in over 100 institutions 
in the United States alone, as well as Europe; efforts to institute trans-
plantation programs in South America and Asia are well beyond the 
developmental stage. By 1989, 1,835 patients had been transplanted at 
our center under cyclosporine and prednisone based immunosup-
pression.38, 47 After 3 years of pre-clinical research, a clinical trial of 
FK506 (tacrolimus) for orthotopic liver transplantation was begun in 
February 1989: First as rescue therapy for patients with intractable 
rejection under conventional immunosuppression, then as part of a 
randomized trial comparing tacrolimus to conventional immunosup-
pression, and finally as a primary drug. 
Initial Clinical Studies with Tacrolimus 
The clinical application of tacrolimus began after extensive labora-
tory research in Chiba, Pittsburgh, and Cambridge.'" 20, 28, 29, 30, 53, 54, 62, 63, 65 
In February 1989 it was used successfully to salvage 8 of 10 liver allograft 
recipients suffering intractable rejection despite optimal cydosporine-
based immunotherapy.50 Further use for this indication accrued over 200 
patients, and was expanded to include recipients of heart, kidney, lung, 
and pancreas allografts. 10, 12 In the patients whose graft dysfunction was 
attributed to acute or the early stages of chronic rejection the success 
rate has been as high as 90%, and even with chronic rejection of the 
liver salvage has approached 50%.12 
Randomized Clinical Trials with Tacrolimus 
After the positive experience with the rescue patients, clinical trials 
using tacrolimus as the primary immunosuppressive agent for recipients 
of liver, kidney, and thoracic organs were initiated.4(,,55 Although there 
was clear evidence of drug superiority with our initial cohort of recipi-
ents, an Institutional Review Board (IRB) mandated trial was begun in 
February 1990 which included a total of 79 low risk patients. In Decem-
LIVER AND INTESTINE TRANSPLANTATION 295 
ber 1991, this trial was discontinued after recommendations from a 
multi-institutional "Patient's Rights Committee," with the concurrence 
of the IRB and the Food and Drug Administration (FDA). 
In the Pittsburgh randomized trial all treatment variables were 
equal including a daily dose of 20 mg prednisone. The occurrence of 
rejection, and the need to treat with added prednisone or other adjuvant 
therapy directly reflected the efficacy of the competing drugs. With the 
"intention to treat analysis" (crediting the end-point outcome to the 
original assigned randomization), the one year patient survival was 
94% tacrolimus versus 89% cyclosporine, and graft survivals were 98% 
tacrolimus versus 80% cyclosporineY However, at the end of 3 1/2 
years the composite freedom from rejection, or graft loss (death or 
retransplantation) was 24% for tacrolimus versus 8% for cyclosporine. 
Freedom from "adverse events" was 6% for tacrolimus versus n;, for 
those originally assigned to cyclosporine. Freedom from rejection alone 
was seen in 33% of patients in the tacrolimus cohort compared to 12% 
for the cyclosporine cohort. At the end of 1 year 51 of the 75 patients 
originally assigned to receive cyclosporine had been converted to tacroli-
mus. It was concluded that tacrolimus was superior to cyclosporine A.l1 
Different although generally congruent information was produced 
by the European27 and AmericanS multi-center trials which supported 
commercial release of tacrolimus by the FDA in June 1994. In the 
European study, although patient and graft survival rates were not 
significantly different (tacrolimus 82.9% and 77.5% versus cyclosporine 
77.5% and 72.6%, respectively), the use of tacrolimus was associated with 
a significant reduction in acute, refractory acute, and chronic rejection 
episodes. Although the survival advantage was not statistically signifi-
cant it was noted that 10'10 of the surviving grafts credited to 
cyclosporine had been rescued with tacrolimus. Toxicity variables were 
similar and comparable.27 In the American study, actuarial patient and 
graft survivals were comparable. It was noted that although tacrolimus 
was associated with significantly lower episodes of acute and refractory 
rejection there were substantially more toxic events requiring discontinu-
ation of tacrolimus.5 However, reanalysis of this data reveals that the 
composite freedom from refractory rejection, retransplantation, and death 
was 80% for the tacrolimus arm versus 70% for the cyclosporine cohort.45 
Primary Therapy with Tacrolimus 
Our clinical experience spans 1,391 consecutive adult and pediatric 
recipients of primary liver allografts treated with tacrolimus between 
August 1989 and December 1993.56 The patient characteristics are sum-
marized in Table 1. Among these 1,391 recipients 85.4% were adults and 
14.6% were children. Of the adult patients 26% were over 60 years of 
age. The most common indication for transplantation was biliary atresia 
in children and post-necrotic cirrhosis in adults. The severity of disease 
for the majority of the patients was high as defined by the existing 
United Network for Organ Sharing (UNOS) criteria: (1) working; (2) 
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Table 1. CHARACTERISTICS OF THE 1391 TACROLIMUS PRIMARY LIVER 
ALLOGRAFT RECIPIENTS 
Total Patient Population 
No. of transplants 
Primary transplantation 
Retransplantation 
Median follow-up months (range) 
Pediatric « 18 yrs) 
Number of patients 
Mean age ± SD 
Indications 
Fulminant failure 
Postnecrotic cirrhosis 
Biliary atresia 
Metabolic disease 
Primary malignancy 
Other 
UNOS Status 
1 
2 
3 
4 
Adult (> 18 yrs) 
No. of patients 
Mean age ± SD 
Indications 
Fulminant failure 
Postnecrotic cirrhosis 
Cholestatic disease 
Metabolic disease 
Primary malignancy 
Other 
UNOS Status 
1 
2 
3 
4 
1391 
1582 
1391 
191 
26.6 (3-55) 
203 
5.4 ± 5.5 
13 (6.4%) 
21 (10.3%) 
99 (48.8%) 
27 (13.3%) 
1 (0.5%) 
42 (20.7%) 
3 (1.5%) 
57 (28.1%) 
72 (35.5%) 
71 (35.0%) 
1138 
50.1 ± 12.0 
20 (2.5%) 
T4E~ (63.0%) 
200 (16.8%) 
38 (3.2%) 
89 (7.5%) 
82 (6.9%) 
5 (0.4%) 
18n (15.9%) 
47G (40.1%) 
518 (43.6%) 
home (but requiring close medical supervision and/ or sporadic hospital 
care); (3) hospital-bound continuously; (4) lCU-bound. 
Clinical Approach to Liver Transplantation 
Immunosuppression 
Our early clinical experience showed dose related nephrotoxicity, 
neurotoxicity, and diabetogenicity, which were paralleled with defective 
metabolism of the drug when there was hepatic graft dysfunction. 1 
These observations prompted progressive dose revisions which were 
guided by a balance between freedom of rejection, toxicity, and trough 
plasma levels of tacrolimus measured with an enzyme immunoassay 
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technique and targeted to 1 ng/mL. Our present policy is to give 
tacrolimus initially intravenously as a continuous infusion at a dose of 
0.05 mg/kg/ day. The conversion from intravenous to oral therapy is 
usually made with a small overlap at a starting oral dose of 0.1-0.15 
mg/kg every 12 hours. 
The steroid administration involved 1 gram of methylprednisolone 
given intravenously immediately after graft reperfusion, followed by a 
5 day burst of methylprednisolone which was started at 200 mg on the 
first day and reduced to a baseline of 20 mg/ day on post-operative day 
6. Appropriately lower doses were given in infants and children. In a 
subsequent phase, the 5 day burst therapy was replaced with a standard 
20 mg/ day of methylprednisolone, the initial high dose steroid burst 
being reserved for positive lymphocytotoxic cross matches.52 With either 
regimen, steroids were weaned over several months and eventually 
stopped if there was no evidence of rejection. 
Clinical diagnosis of rejection was confirmed by a needle biopsy. 
Initial therapy for rejection included optimization of maintenance tacroli-
mus levels and bolus therapy with methylprednisolone or hydrocorti-
sone. Persistence of rejection was treated with 5 day burst therapy using 
methylprednisolone. Steroid resistant rejection was treated with a 3 to 5 
day course of 5-10 mg/day of monoclonal antibody to the T cell receptor 
(OKT3). Azathioprine (0.5-2 mg/kg/ day) was given in cases of recurrent 
rejection or evidence of clinical toxicity necessitating the reduction of 
tacrolimus trough levels. 
Patient survival was calculated from the date of transplantation 
until patient death, and graft survival was calculated from the date of 
transplantation until retransplantation or patient death. Survival curves 
were generated using the life table method. 
Results 
With a mean follow-up of 29.6 months (range: 3-55), the overall 
patient actuarial survival rates in children were 91.1%, 89.6%, 88.5%, 
88.5%, and 86.2%, at 3, 6, 12, 24, and 48 months, respectively, and in 
adults were 89.7%, 86.6%, 82.1 %, 77.?D/o, and 71.4%, at 3, 6, 12, 24, and 
48 months, respectively (Fig. 1). There were a total of 1,582 liver allo-
grafts. The overall graft survival in children was 81.4%, 80.1%, 79.1%, 
and 77.0% at 3, 6, 12 and 48 months, respectively, and in adults were 
80.3°;\), 76.5%, 72.0%, and 61.5% at 3, 6, 12, and 48 months, respectively 
(Fig. 2). The causes for primary graft failure due to rejection were only 
18 grafts (1.5%) seen in only the adult population. Greater than 50% of 
these liver recipients were rejection free. Nearly half of the adult recipi-
ents and over 90% of the pediatric recipients were steroid free by 3 
months after transplantation. Retransplantation was required in 9.9% of 
pediatric recipients and 9.8% of adult recipients (Table 2). The difference 
between patient and graft survival emphasizes the survival benefit of 
retransplantation. 
Death was attributable to either technical failure (mostly hepatic 
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Figure 1. Patient survival for primary liver allograft recipients who received FK506 (Tacroli-
mus) as the primary immunosuppressive drug therapy. 
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Figure 2. Overall graft survival using FK506 (Tacrolimus) as the primary immunosuppres-
sive drug therapy. The difference between patient and graft survival emphasizes the 
survival benefit of retransplantation. 
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Table 2. INCIDENCE AND CAUSE OF RETRANSPLANTATION OF PRIMARY GRAFT 
Pediatric Patients 
No. of patients 
No. of retransplantations 
Causes 
Technical failure 
Rejection 
Graft infection 
Graft failure 
Disease recurrence 
Other 
Adult Patients 
No, of patients 
No. of retransplantations 
Causes 
Technical failure 
Rejection 
Graft failure 
Other 
Graft infection 
Disease recurrence 
203 
20 (9,9%) 
6 (3.0%) 
o 
1 (0.5%) 
13 (6.4%) 
o 
o 
1188 
116 (9,8%) 
28 (2.4%) 
7 (0.6%) 
76 (6.4%) 
2 (0.2%) 
3 (0.3%) 
o 
artery thrombosis, or bile duct complications), sepsis, and immunologi-
cally related complications which included rejection, graft-versus-host 
disease (GVHD), and posttransplant lymphoproliferative disorders 
(PTLD) (Table 3). 
Other aspects of our experience with drug toxicity, drug interac-
tions, opportunistic infections, and other clinical observations have been 
published elsewhere.3, 4, 1',16, 35 
INTESTINAL TRANSPLANTATION 
Total parenteral nutrition (TPN) is the standard of care for patients 
who are unable to maintain a normal nutritional state by the gastrointes-
tinal tract alone. Transplantation of the intestine either alone or accompa-
nied by other intra-abdominal organs (liver, stomach, pancreas, colon) 
may be beneficial in these patients. Loss of intestinal function may be 
attributed to loss of bowel length after resections for atresias, infarctions 
(volvulus, vascular catastrophes, necrotizing enterocolitis), or strictures 
and fistulas as with Crohn's disease and radiation enteritis. When the 
anatomic length and gross morphology of the intestine is normal, the 
functional loss can be attributed to motility disorders (intestinal pseudo-
obstruction, Hirschsprung's disease), absorptive insufficiencies (micro-
villus inclusion disease), polyposis syndromes, and incarcerated tumors, 
A multi-disciplinary team must assess the baseline disease as well 
as the severity of other co-morbid states, particularly liver failure and 
its accompanying gamut of complications. Appropriate selection of can-
didates and optimization of preoperative morbid conditions (infection, 
300 REYES et al 
Table 3. INCIDENCE AND CAUSE OF MORTALITY 
Pediatric Patients 
No. of Patients 
No. of mortalities 
Causes 
Technical failure 
Sepsis 
Immunusuppression related 
Extrahepatic event 
Disease recurrence 
Graft failure 
Other 
Adult Patients 
No. of Patients 
No. of mortalities 
Causes 
Technical failure 
Sepsis 
Immunosuppression related 
Other 
Graft failure 
Disease recurrence 
Extrahepatic event 
203 
18 (8.9%) 
6 (3.0%) 
1 (0.5%) 
1 (0.5%) 
3 (1.5%) 
o 
7 (3.4%) 
a 
1188 
119 (10.1%) 
OO~ (1.9%) 
3::: (2.8%) 
9 (O.8%) 
1 (0.1 %) 
33 (2.8%) 
1 (O.1%) 
20 (1.7%) 
malnutrition) can have a major impact on outcome. Critically ill patients 
should be excluded. Multiple previous abdominal surgery is not a con-
traindication for transplantation. 
Early Experimental and Clinical Studies 
Experimental and clinical intestinal transplantation have been 
through several developmental phases over the last 30 years.21,48 Success 
remained blurred because of a high incidence of graft loss due to 
infection, technical complications and rejection. Rejection and the pre-
dicted counterpart of GVHD were two problems that were expected 
with intestinal transplantation. 
Two events helped bring intestinal transplantation to the forefront 
of clinical practice. First was the demonstration in clinical liver trans-
plantation of the greater efficacy of tacrolimus as described in the previ-
ous section. Then, recent laboratory and clinical research with intestinal 
transplantation played a critical role in establishing a generic bi-direc-
tional paradigm of transplantation and immunology that is relevant to 
all organs.17, 24, 48, 59 
This reassessment began after a series of human applications of the 
modified form of this operation, which began in 1987 when a 3-year-old 
girl received a multivisceral abdominal graft that contained the stomach, 
duodenum, pancreas, small bowel, colon, and the liver. She had an 
extended survival of 6 months with good intestinal graft function with-
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out developing either rejection or GVHD.49 The cadaveric organs of this 
recipient were depleted of T lymphocytes by infusing the donor with 
OKT3 treatment before procurement and by ex-vivo irradiation after 
their removal. This type of preconditioning was suspected to have 
contributed to the wide spread B-cell lymphoma that caused the death 
of this child. Subsequently 4 more patients achieved functional cadaveric 
intestinal grafts when transplanted alone,14 as liver/intestinal composite 
graft,15,23 or as multivisceral allografts.39 Only the intestine-alone recipi-
ent of Goulet and Revillon14 is alive with a functioning graft, while two 
liver !intestinal recipients of Grant15, 23 survived for 58 and 66 months, 
Also, a living related donor intestinal segment was transplanted by 
Deltz7 in February 1988 which supported nutrition for 61 months. All 
the above transplants were performed under cyclosporine based immu-
nosuppression. 
Present Patient Population 
We have performed 71 intestinal transplantations in 67 patients 
between May 1990 and February 1995.57 There were 3 types of intestinal 
allografts which are shown in Figure 3: isolated intestinal (n = 23), com-
bined intestine/liver (n = 32), and multivisceral (n = 11). Those patients 
with satisfactory liver function without evidence of portal hypertension 
received an isolated intestinal allograft Patients with inborn errors and 
also TPN induced cholestatic liver disease received a liver plus intestinal 
allograft The multivisceral type allograft was indicated in patients who 
had extensive abnormalities of the entire gastrointestinal tract which 
included absorptive/secretory, motility, or vascular disorders. The prin-
ciples and various modifications of these procedures have been de-
scribed elsewhere.1s, 51, 58, 60, 61 The colon was included as part of the 
allograft midway through our experience with intestinal transplantation 
in all 3 recipient cohorts, This was prompted by high post-operative 
stomal outputs requiring frequent admissions for dehydration, 
Our more recent experience also involves including bone marrow 
infusion at the time of intestinal transplantation. Bone marrow cells 
were recovered from the same donor as the intestine and were infused 
intravenously into the recipient in the immediate post-operative period 
in 4 recent cases (3 primary and 1 retransplantation). The rationale for 
this approach of including simultaneous bone marrow infusion after 
solid organ transplantation was derived from experimental and clinical 
evidence that the existence of "chimerism" is critical for graft 
acceptance.9,26 
There were 37 children, 16 male and 21 female with a mean age of 
4.3 ± 4.2 years, Twenty-nine patients were adults, 16 male and 13 
female, with a mean age of 33.3 ± 9.5 years. The original diseases 
leading to transplantation are as listed in Table 4. All patients have been 
followed through April 1995. Median follow-up was 21 months ranging 
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Table 4. CAUSES OF INTESTINAL FAILURE 
Children 
Volvulus 
Gastroschisis 
Necrotizing enterocolitis 
Intestinal atresia 
Pseudo-obstruction 
Microvillus inclusion disease 
Intestinal polyposis 
Hirschsprung's disease 
Total 
9 
8 
6 
6 
3 
3 
1 
1 
37 
Adults 
Thrombotic disorder 
Crohn's disease 
Desmoid tumor 
Intestinal trauma 
Intestinal adhesions 
Pseudo-obstruction 
Malignant gastrinoma 
Volvulus 
Total 
8 
7 
5 
4 
2 
1 
1 
1 
29 
from 1.5 to 57 months. All but 4 of our most recent cohort of recipients 
have been followed for 1 year post-transplantation. 
All donors were cadaveric of the identical ABO blood type as the 
recipients. Matching of human leukocyte antigen (HLA) was random 
and uniformly poor. The lymphocytotoxic cross match was positive in 7 
patients. A history of normal intestinal function in a potential liver 
donation referral is adequate for possible intestinal donation. The pro-
curement of multiple visceral organs focuses on the isolation and cooling 
of these organs, preserving their vascular and parenchymal anatomy. 
The organs are flushed with University of Wisconsin (UW) solution.B 
The cold ischemic time averaged 7.7 ± 2.4 hours. 
Immunosuppression 
Immunosuppression consisted of tacrolimus and low dose steroids, 
to which prostaglandin E1 was added briefly during the early post-
operative stage. Adjustment of tacrolimus dosing and/ or supplemental 
use of steroids, OKT3, and azathioprine were given for the treatment of 
rejection episodes. This was based on severity and/ or tacrolimus related 
toxicity as previously described.3 Other aspects of toxicity as well as 
infectious disease complications and complex nutritional management 
are as described elsewhere.2,36 
Figure 3. The three types of intestinal allografts: intestine alone (right), liver/intestine (left), 
and multivisceral (middle). IVC = portal vein; HA = hepatic artery; SMA = superior 
mesenteric artery; SMV = superior mesenteric vein; SA = splenic artery; LGA = left 
gastric artery. Colonic segments (shaded) were included in 29 recipients scattered through 
the three cohorts. (From Todo S, Reyes J, Furukawa H, et al: Outcome analysis of 71 
clinical intestinal transplantations. Ann Surg 222:270-282, 1995; with permission.) 
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Results of Clinical Trials 
During the potential follow-up of 1 to 5 years and as of April 1995, 
32 patients (48.5'X)) are still alive. The actuarial survival rate for the 63 
patients at 3, 6, 12, and 24 months was 84.1%, 80.9';\', 72.8%, and 57.5°/." 
respectively. The estimated actuarial survival for an types of grafts was 
73.5%, 70.5%, 62.8%, and 48.1 'Yo at 3, 6, 12 and 24 months, respectively 
(Fig. 4). There was no survival difference between the 3 types of trans-
plant procedures or between the pediatric and adult age groups (Fig. 5). 
Of the 32 surviving patients, 28 still bear their primary allografts which 
are functional. Only 1 patient requires intermittent night time intrave-
nous hydration. The remaining 4 patients returned to TPN after graft 
removal and 1 recently underwent a successful retransplantation. Graft 
survival was similar in adults and children. 
Death was the cause of primary graft loss in 3E; recipients. Surgical 
removal of the graft followed by immediate attempted retransplantation 
occurred in 4 recipients, and there was surgical removal of the graft and 
return to hyperalimintation in another 4 recipients. The principal reasons 
for primary graft losses included surgical or clinical management fail-
ures which caused the death of the recipient. In 8 recipients the grafts 
were functioning at or shortly before the time of death. Technical surgi-
cal failures were more common in children and included intestinal 
anastomotic leaks, hepatic artery thrombosis, biliary anastomotic leaks, 
and cerebral infarction associated with intraoperative cardiac arrest. 
There was 1 recipient who was non-compliant and developed chronic 
rejection of the intestinal allograft. 
~ ~ 
;;; 
> 
K~ 
::J 
en 
100 
80 
60 
40 
20 
~ ...... 
............. 
.......................... 
• • • • 
.......................................... 
Patient (n=63) 
.....•.... Primary Graft (n=63) 
o+---~---K----~--K--------I----~--~ 
o 2 3 4 
Time After Transplantation (years) 
Figure 4. Actuarial patient and allograft survival of the first 63 reCipients. (From Todo S, 
Reyes J, Furukawa H, et al: Outcome analysis of 71 clinical intestinal transplantations. Ann 
Surg 222:270-282, 1995; with permission.) 
~ e.... 
C1l 
> 
. ~ 
:;, 
en 
E 
K~ 
iii 
a. 
100 . 
80 
60 
40 
20 
LIVER AND INTESTINE TRANSPLANT A nON 305 
':. 
',\ 
":.'.'-JI! 
1. ... .,.\...6.. 
... "1t. 
' .. - -. ~"" 
, ..... 
----- ..... 
.....•.... 
", ............ . 
.....•....• " 
" " 
". -.-...,.. ........ _--
• .. ··········::·'1::::1::::1::::1····.··· .• 
Isolated Intestine (n=22) 
Liver and Intestine (n=30) 
Multivisceral (n=11) 
l+---~---K----~--K---~----~--~--~ 
o 2 3 4 
Time After Transplantation (years) 
Figure 5. Allograft survival with the three different types of procedures_ (From Todo S, 
Reyes J, Furukawa H, et al: Outcome analysis of 71 clinical intestinal transplantations. Ann 
Surg 222:270-282, 1995; with permission.) 
Reasons for the loss of the other 25 allografts included an array of 
factors which were interlocking and complex. The principal diagnosis 
was rejection in only 6 cases, whereas infection as a complication attrib-
utable to the immunosuppressive therapy was the major diagnosis in 19 
recipients. Bacteria and fungi were accountable for 6 such complications; 
however, cytomegalovirus (CMV) (n=5) as well as Epstein-Barr virus-
associated post-transplant lymphoproliferative disease (PTLD) (n = 12) 
were responsible for significant morbidity. Eight of the 12 patients who 
developed PTLD died due to this complication. 
Retransplantation was performed in 4 patients on the same day as 
primary graft removal (2 liver/intestine) or 1 to 2 months post removal 
of the primary allograft (2 intestinal recipients only). All retransplantated 
patients died between 47 and 147 days after the second transplant, with 
the diagnosis of rejection (n = 2), PTLD (n = 1), and sepsis (n = 1). Also, 
an isolated liver retransplantation was performed in a pediatric recipi-
ent who developed thrombosis of the hepatic artery after a combined 
liver /intestinal graft. A fifth intestinal only retransplantation was carried 
out in a recipient who had received an intestine only 11 months after 
graft enterectomy. This patient tolerated retransplantation and was given 
bone marrow with the second intestinal allograft. 
Analysis of these cases has yielded 6 statistically significant risk 
factors for graft loss and death: high tacrolimus blood trough levels, 
bolus steroid therapy, OKT3 use for treatment of allograft rejection, 
length of operation, CMV positive status of donor and recipient, and an 
inclusion of a segment of colon with the transplanted allograft. The 
survival of serologically CMV-negative recipients when they receive a 
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CMV -negative donor allograft was 62% versus 47% when the donor 
allograft was CMV positive. Also, an adverse effect was noted when the 
recipient was already CMV positive at transplantation, with a survival 
of 54% if the donor allograft was CMV negative, but only 14% when the 
donor allograft was CMV positive. The predominant site of CMV disease 
was the intestinal allograft, and therapy for this disease was marginally 
effective in these intestinal transplant recipients. Inclusion of a segment 
of donor colon in the allograft in 29 cases showed a significantly inferior 
survival than when the colon was not included. 
Two of the augmented patients received an isolated intestinal allo-
graft and 2 were given liver plus intestine. One recipient was an isolated 
intestinal retransplant recipient who had a previous history of PTLD 
that had been in remission since discontinuance of the immunosuppres-
sion and removal of his primary allograft 11 months previously. 
Evidence of donor cells was detected in all 4 bone marrow aug-
mented bowel recipients by either PCR and/ or flow cytometry. In the 
female recipient who received a male allograft, presence of donor cells 
was confirmed by fluorescence in situ hybridization for the Y chromo-
sOlne. No evidence of CVHD was found in any of the 4 recipients who 
were given bone marrow cells. 
CHIMERISM AND THE INDUCTION OF GRAFT 
ACCEPTANCE 
Until recently, insights into the acceptance of a transplanted organ 
by the recipient immune system were focused on manipulations of the 
recipient cell population with the use of immunosuppressive drugs. This 
experience allowed for improved survival after organ transplantation 
and the development of therapeutic dogmas to which we have adhered 
tenaciously. Interestingly, most patients progressively require less and 
less immunosuppressive therapy, and some have discontinued therapy 
altogether. 37 
Since 1969 it was noted that Kupffer cells and other tissue leukocytes 
became predominantly of the recipient phenotype within 100 days after 
transplantation while the hepatocytes retain their donor specificity per-
manently.l,! Twenty-two years later other insights emerged regarding 
allograft acceptance, which were based on the observation that donor 
leukocytes from transplanted organs had migrated and survived 
throughout the body of the recipient for as long as three decades.39,4l1, 
n, H This process occurred in all successfully transplanted organs, the 
liver being the most tolerogenic transplanted organ because of its much 
larger total leukocyte load as well as its lineage profile of the migratory 
leukocytes. The events following transplantation were then seen as a 
two way cellular action-graft versus host (CVH) and host versus graft 
(HVC). Under the cover of immunosuppressive drugs (traffic directors) 
the graft as well as the recipient become genetic composites composed 
of cells of both parties (Fig. 6). 
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Figure 6. Under the cover of immunosuppressive drugs (traffic directors) there is a mutual 
engagement of migratory multilineage immunocytes between the graft and the recipient, 
which become genetic composites composed of cells of both parties. GVH = graft versus 
host; HVD = host versus graft. (From Starzl TE, Demetris AJ, Murase N, et al: Donor cell 
chimerism by immunosuppressive drugs: A new view of organ transplantation. Immunol 
Today 14:326, 1993; with permission.) 
This bidirectional migration has been particularly dramatic in all 
successfully transplanted intestines, and was also observed at different 
proportions in the liver, kidney, and heartY' 25, 31, 13 Here, since neither 
the recipient nor the graft is leukocyte depleted, it is possible to routinely 
perform intestinal and multivisceral transplantation without an exorbi-
tant risk of graft versus host disease (GVHD). This spontaneous 
"chimerism" after whole organ transplantation differs from bone mar-
row transplantation in that the treatment strategy involved empirically 
leaving both cell populations intact. This reciprocal interaction (mutual 
natural immunosuppression) may blindfold the major histocompatibility 
complex effect, thus removing tissue matching as a crucial requisite for 
success, and largely eliminates the threat of GVHD.4J 
Evidence supporting chimerism was found in retrospective studies 
of long-term survivors of kidney allografts (30 years post-transplanta-
tion), liver allografts (10-21 years post-transplantation) and recipients of 
thoracic organs.42,64 The identity of donor and recipient cells was estab-
lished after special staining procedures (immunostaining or sex identifi-
cation after fluorescence in situ hybridization [FISH]), and polymerase 
chain reaction [DNA fingerprinting]). 
The observation of surviving donor multiline age passenger leuko-
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cytes being associated with organ graft acceptance permits us to view 
the engraftment of any whole organ in the same context as a "mini" 
bone marrow transplantation. The acceptance of this concept inherently 
brings about the question of eventually stopping immunosuppressive 
medication altogether. Many non-compliant patients have stopped their 
medications sporadically and then completely when all liver functions 
remained normal. Other patients have had their immunosuppression 
withdrawn because of infectious complications.37 Because complications 
of immunosuppression have been the principal cause of late death in 
our long-term surviving recipient population, a prospective, physician-
directed weaning trial was begun. This involved the systematic decrease 
in the baseline immunosuppression in patients suffering complications 
of long-term immunosuppression.32 Complete weaning was accom-
plished in 16 patients (27.1 %) with 3-19 months drug-free follow-up, is 
progressing in 28 (47.4%), and failed in 15 (25.4%). Patients who failed 
the weaning trial were restored to their baseline immunosuppression 
regimen. There were no grafts lost or significant loss of graft function 
from the rejections. This and our previous experience with patients off 
immunosuppression indicates that cautious weaning can be performed 
safely and under careful surveillance 5 to 10 years after transplantation.J2 
The strategy of augmenting this natural migratory traffic would 
supplement the minimal dose of the passenger leukocytes (which are of 
bone marrow origin) and thus enhance the natural chimerism. Since 
March 1993 such a prospective trial has been under way at the Univer-
sity of Pittsburgh by infusing 3 X 108 unaltered donor bone marrow 
cells (obtained from the thoraco-Iumbar vertebrae of the cadaveric 
donor) perioperatively into an unmodified recipient.9,34 This trial pres-
ently includes 64 patients that have been simultaneously transplanted 
with donor bone marrow and liver (n=28), liver and islets (n=I), 
kidney (n = 17), kidney and pancreas (n = 2), kidney and islets (n = 6), 
heart (n = 8), and lungs (n = 8). All patients were maintained on routine 
immunosuppression with tacrolimus and prednisone. Also, 53 recipients 
of whole organ allografts in whom consent to retrieve donor vertebral 
column was not available were monitored as contemporaneous controls. 
No complication of bone marrow infusion was observed in any of 
the patients. Four of the 9 kidney/bone marrow recipients were able to 
come off steroids versus none of the kidney transplant alone recipients. 
The liver allograft recipients show similar graft function in both groups. 
All 3 recipients of pancreatic islet cells are currently being maintained 
on exogenous insulin. Similar episodes of rejection were seen in 58% of 
bone marrow-augmented and 64°/., of control patients. Asymptomatic 
GVH reaction in the skin was seen in only 2 patients (recipients of 
liver/bone marrow), which completely regressed with slight increase in 
baseline steroid therapy in 1 patient and no therapy in the other. Evi-
dence of circulating donor cells by flow cytometry, PCR, or fluorescence 
in situ hybridization was present in 18 of 18 study patients and in 9 of 
21 control patients. Using in vitro testing by MLR it was possible to 
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show evidence of evolving donor-specific hyporeactivity in 41 % of bone 
marrow augmented patients and 18% of control patients. 
Although all patients are still receiving immunosuppressive ther-
apy, these data suggest that simultaneous infusion of donor bone mar-
row at the time of whole-organ transplantation may lead to augmen-
tation of chimerism. The timing and eventual progress to a drug-free 
state remains speculative. 
SUMMARY 
The evolution of tacrolimus immunosuppression for recipients of 
liver allografts has substantiated our belief in the clinical superiority 
compared to cyclosporine. This was shown in our initial cohort of 
patients, as well as randomized liver transplant recipients. Results of 
the multi-center trials conducted in Europe and the United States are 
congruent with this conclusion. In these randomized trials, crossover 
from cyclosporine to tacrolimus because of intractable rejection (but not 
vice versa) was a common event that frequently prevented death or 
the need for retransplantation. We believe tacrolimus will supplant 
cyclosporine as the principal baseline immunosuppressive drug for 
transplantation of the liver and other organs. Not only was there im-
proved patient and graft survivals, but also observed was an improve-
ment in the associated quality of life due to a lower need for steroids, 
and fewer cosmetic side effects which is of particular importance in the 
pediatric population. 
There is a significantly better understanding of not only the mecha-
nisms of tacrolimus but also of a previous epiphenomenon such as 
"chimerism," which at the present time we believe is the central event 
responsible for graft acceptance. The observation of surviving donor 
multilineage passenger leukocytes being associated with organ graft 
acceptance implies a persistent engagement of donor and recipient im-
munocytes with consequent development of various degrees of donor 
specific non-reactivity. This is of particular importance in recipients of 
intestinal grafts, where recipient-specific non-reactivity of the chimeric 
donor cells must occur if the patient is to escape the complication 
of GVHD. 
We are presently armed with a new potent immunosuppressive 
drug, tacrolimus, and an understanding that the migration and grafting 
of "passenger leukocytes" of bone marrow origin is the seminal explana-
tion for allograft acceptance. The next forefront will involve manipula-
tion of this process not only for the transplantation of already successful 
whole organs such as liver, kidney, pancreas and heart, but also in the 
development of the intestinal transplantation program. Thus, augmen-
tation of the leukocyte traffic of unconditioned recipients of cadaver 
whole organ allografts by the concomitant intravenous infusion of donor 
bone marrow cells and under the same conditions of immunosuppres-
sive management of tacrolimus/prednisone treatment will be our path 
into the future. 
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